MIMICT for Nephrology Providers
The purpose of this education activity is to educate nephrology providers on:
- The importance of African American and Latino patient participation in lupus clinical trials.
- The lack of participation by these minorities in clinical trials.
- How to help recruit these minorities with lupus into clinical trials.
Nephrology providers, including MDs, DOs, PAs, NPs, RNs, and other medical providers who work in nephrology
Learning ObjectivesUpon completion of this activity, participants should be able to do the following:
- Discuss lupus-related health disparities
- Understand provider barriers to clinical trial recruitment
- Implement communication strategies between providers and patients about clinical trials
- Understand simplified approaches to learn about local clinical trials for your patients
Registration FeesRegistration is complimentary.
CME and MOC Information
The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The ACR designates this online activity (enduring material) for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activities.
CME credit must be claimed by 11:59 PM ET, September 30, 2025.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participation completion information to the ACCME for the purpose of granting ABIM MOC credit.By completing this activity you provide the ACR permission to share completion data with the ACCME and the certifying board(s).
Faculty and Disclosures
ACR Disclosure Statement
It is the policy of the American College of Rheumatology (ACR) to ensure that Continuing Medical Education (CME) activities are independent and free of commercial bias. To ensure educational content is objective, balanced, and guarantee content presented is in the best interest of its learners' and the public, the ACR requires that everyone in a position to control educational content disclose all financial relationships with ineligible companies within the prior 24 months. An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Examples can be found at accme.org.
Nature of Financial Relationships
Faculty participating in an ACR-sponsored activity must disclose to the planning committee and audience all financial relationships with ineligible companies any financial or other relationship(s) with a ineligible company including, but not limited to:
- Advisor or review panel member
- Officer or Board Member
- Grant/research support
- Speaker/honoraria includes speakers bureau, symposia, and expert witness
- Independent contractor
- Ownership Interest
- Intellectual property/patents
- Stock options or bond holdings in a for-profit corporation or self-directed pension plan
- Other financial or material support
None: Has no relevant financial relationship(s) with ineligible companies to disclose.
The Faculty reported the following disclosures:
- Saira Sheikh, MD: GlaxoSmithKline2; Aurinia Pharmaceuticals, Inc.2; AstraZeneca2; Lilly USA, LLC2; Pfizer5
- Donna Culton, MD, PhD: Alkahest2, Argenx2, Aria2, Kezar2, Principia5, Cabaletta5
- Allen Anandarajah, MD, MS: None
- Wendy Rodgers, MPH: None
- TramAnh Phan, MD: None
- Irene Blanco, MD: Novartis6
- Rosalind Ramsey-Goldman, MD, DrPH: Aurinia2, AstraZeneca6, Biogen2, ThermoFisher2
- Titilola Falasinnu, PhD: None
- Candace Feldman, MD: None
- Kimberly Trotter, MD: None